New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:36 EDTTHLDThreshold Pharmaceuticals reports updated Phase 2 Results for TH-302
Threshold Pharmaceuticals announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin. The results were reported at the 17th annual meeting of the Connective Tissue Oncology Society, or CTOS, taking place Nov. 14-17, in Prague, Czech Republic. Results for Overall Study Population-- Updated results for the 91 patients in the Phase 2 component of the study include: Median progression free survival, or PFS, of 6.7 months. Median overall survival of 21.5 months. One-year survival of 73%, and two-year survival of 44%. Overall best response of 36%. Results for TH-302 Single Agent Maintenance Therapy Population -- Of 91 patients enrolled in the study, 48, or 53%, continued on TH-302 maintenance therapy. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18.0 months. Overall best response (partial and complete responses, unconfirmed) of 54%; five patients who previously had stable disease prior to maintenance achieved a partial response, and one patient who previously had a partial response achieved a complete response.
News For THLD From The Last 14 Days
Check below for free stories on THLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
09:15 EDTTHLDOn The Fly: Pre-market Movers
HIGHER: Sigma-Aldrich (SIAL), up 34% after Merck KGaA (MKGAY) to acquire the company for $17B... Viasystems (VIAS), up 44% after TTM Technologies (TTMI) acquires the company for $16.46 per share in cash and stock. TTM is up 15.5% after the deal... Clorox (CLX), up 5.4% after the New York Post said the company turned down offer to sell or merge with rival... EMC (EMC), up 2.5% after The Wall Street Journal said the company is considering options that could include merging with a rival and held on-and-off merger talks with Hewlett-Packard (HPQ) for almost a year, though the Journal added that those talks recently ended... Epiq Systems (EPIQ), up 9.9% after P2 Capital confirms 16.9% stake in Epiq and that the company turned down the shareholders' $20 per share takeover offer... Dresser-Rand (DRC), up 2.7% after the company sells to Siemens (SIEGY) for $83 per share or $7.6B... TAT Technologies (TATT), up 6.6% after a division of the company signed a maintenance agreement with Republic Airways (RJET). LOWER: Yahoo (YHOO), down 2.1% after stock was downgraded at Bank of America Merrill Lynch and at Bernstein... InvenSense (INVN), down 2.9% after downgraded at RW Baird... Threshold Pharmaceuticals (THLD), down 5.6% after TH-302 Phase 3 trial events to occur later than expected.
08:07 EDTTHLDThreshold Pharmaceuticals announces TH-302 Phase 3 trial will continue
Threshold Pharmaceuticals announced that the Independent Data Monitoring Committee, or IDMC, has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma, or STS. Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion. Threshold and its partner Merck KGaA, Darmstadt, Germany, have been and will remain blinded to the data from the trial. Based on projections derived from the interim analysis, Threshold is revising its guidance on timing for the number of events required for the primary efficacy analysis. Previously, the company projected the pre-specified number of events would occur around the middle of 2015; the revised projections suggest the requisite events will occur in the latter half of 2015.
September 19, 2014
14:20 EDTTHLDThreshold Pharmaceuticals volatility elevated on wide price movement
Subscribe for More Information
September 9, 2014
11:17 EDTTHLDHigh option volume stocks
Subscribe for More Information
09:12 EDTTHLDOn The Fly: Pre-market Movers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use